Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Voyager Therapeut (VYGR)

Voyager Therapeut (VYGR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 511,978
  • Shares Outstanding, K 37,073
  • Annual Sales, $ 7,620 K
  • Annual Income, $ -88,290 K
  • 60-Month Beta 2.49
  • Price/Sales 68.02
  • Price/Cash Flow N/A
  • Price/Book 4.77

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.85
  • Number of Estimates 5
  • High Estimate -0.62
  • Low Estimate -1.04
  • Prior Year -0.70
  • Growth Rate Est. (year over year) -21.43%

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.31 +13.32%
on 11/18/19
14.80 -5.74%
on 11/11/19
-0.91 (-6.12%)
since 11/08/19
3-Month
12.31 +13.32%
on 11/18/19
18.80 -25.80%
on 09/20/19
-3.12 (-18.28%)
since 09/10/19
52-Week
7.76 +79.77%
on 01/24/19
28.79 -51.55%
on 06/20/19
+2.91 (+26.36%)
since 12/10/18

Most Recent Stories

More News
Voyager Therapeutics (VYGR) Reports Q3 Loss, Tops Revenue Estimates

Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of 50.60% and 419.00%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?...

VYGR : 13.95 (+1.01%)
Voyager Therapeutics: 3Q Earnings Snapshot

CAMBRIDGE, Mass. (AP) _ Voyager Therapeutics Inc. (VYGR) on Wednesday reported a loss of $15 million in its third quarter.

VYGR : 13.95 (+1.01%)
Voyager Therapeutics Announces Third Quarter 2019 Financial Results and Corporate Highlights

Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today reported its third quarter 2019 financial...

VYGR : 13.95 (+1.01%)
Voyager Therapeutics to Present at the Credit Suisse Healthcare Conference

Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced a management presentation...

VYGR : 13.95 (+1.01%)
Voyager Therapeutics to Host Third Quarter 2019 Financial Results and Corporate Highlights Conference Call

Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced that it will report its...

VYGR : 13.95 (+1.01%)
Canadian Securities Exchange Reports Strong Trading Activity, Listings Growth and Other Milestones in Third Quarter of 2019

Toronto, Ontario--(Newsfile Corp. - October 16, 2019) - The Canadian Securities Exchange ("CSE" or "the Exchange") today announced performance and operating highlights for the third quarter ("Q3 2019")...

BFGC : 0.1100 (+4.76%)
INNO : 0.0035 (+2.94%)
RVVTF : 0.0207 (-21.29%)
VYGR : 13.95 (+1.01%)
BLLG.CN : 1.330 (+2.31%)
MGRO.CN : 0.640 (unch)
BHNG.CN : 0.090 (unch)
SWIS.CN : 0.145 (+107.14%)
MGXR.CN : 0.110 (-4.35%)
RVV.CN : 0.030 (unch)
WAL.CN : 0.200 (+100.00%)
XPHY.CN : 0.960 (+1.05%)
CRUZ.CN : 0.030 (unch)
NUGT.CN : 0.120 (+50.00%)
CIG.CN : 0.020 (-42.86%)
AYR-A.CN : 11.760 (-1.34%)
VC.CN : 0.100 (-28.57%)
XCX.CN : 0.195 (-11.36%)
QSC.CN : 0.095 (-13.64%)
CRS.CN : 0.650 (-7.14%)
BFG.CN : 0.130 (-13.33%)
PIKE.CN : 0.110 (unch)
XS.CN : 0.190 (-5.00%)
VYGR.CN : 0.280 (-11.11%)
YT.CN : 0.090 (-18.18%)
CRC.CN : 0.045 (+125.00%)
IMCX.CN : 0.520 (unch)
WIKI.CN : 0.130 (+8.33%)
Voyager Therapeutics to Present at Upcoming Investor Conferences in October 2019

Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced management presentations...

VYGR : 13.95 (+1.01%)
Voyager Therapeutics to Present at Upcoming Investor Conferences in September 2019

Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced management presentations...

WFC : 53.69 (-0.43%)
VYGR : 13.95 (+1.01%)
Voyager Therapeutics (VYGR) Q2 Earnings and Revenues Top Estimates

Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of 132.95% and 777.85%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

VYGR : 13.95 (+1.01%)
Voyager Therapeutics: 2Q Earnings Snapshot

CAMBRIDGE, Mass. (AP) _ Voyager Therapeutics Inc. (VYGR) on Friday reported second-quarter net income of $11.2 million, after reporting a loss in the same period a year earlier.

VYGR : 13.95 (+1.01%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade VYGR with:

Business Summary

Voyager Therapeutics, Inc. is a gene therapy company. It focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. Its pipeline includes VY-AADC01, which is in Phase 1b clinical trials for treatment of Parkinson's disease and preclinical programs...

See More

Key Turning Points

2nd Resistance Point 14.59
1st Resistance Point 14.27
Last Price 13.95
1st Support Level 13.66
2nd Support Level 13.37

See More

52-Week High 28.79
Fibonacci 61.8% 20.76
Fibonacci 50% 18.28
Fibonacci 38.2% 15.79
Last Price 13.95
52-Week Low 7.76

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar